The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 121, Issue , 2016, Pages 184-191

  Guo, Heming ^a   Fang, Chen ^a   Huang, Yun ^a   Pei, Yufang ^b   Chen, Linqi ^c   Hu, Ji ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

DPP4 inhibitors; Meta analysis; Type 1 diabetes

Indexed keywords

ALOGLIPTIN; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL PAIN; ARTICLE; ASIAN; CASE STUDY; CAUCASIAN; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NAUSEA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; DIABETES MELLITUS, TYPE 1; METABOLISM;

DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84991447932     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.08.022     Document Type: Article

References (29)

1. [1] Atkinson, M.A., Eisenbarth, G.S., Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358 (2001), 221–229.
2. [2] Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
3. [3] Park, H., Park, C., Kim, Y., Rascati, K.L., Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 46:3 (2012), 1453–1469.
4. [4] Giorda, C.B., Nada, E., Tartaglino, B., Pharmacokinetics, safety, and efficacy of DPP4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46 (2014), 406–419.
5. [5] Deacon, C.F., Holst, J.J., Dipeptidyl peptidase-4 inhibitors for the treatment of Type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 14 (2013), 2047–2058.
6. [6] Ellis, S.L., Moser, E.G., Snell-Bergeon, J.K., Rodionova, A.S., Hazenfield, R.M., Garg, S.K., Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 28 (2011), 1176–1181.
7. [7] Zhao, Yunjuan., Yang, Lin, Xiang, Yunfei, Liu, Lingjiao, Zhou, Zhiguang, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. J Clin Endocrinol Metab 99:5 (2014), E876–E880.
8. [8] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8 (2010), 336–341.
9. [9] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327:7414 (2003), 557–560.
10. [10] Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
11. [11] Guyatt, G., Oxman, A.D., Akl, E.A., Kunz, R., Vist, G., et al. GRADE guidelines: introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64 (2011), 383–394.
12. [12] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed) 315 (1997), 629–634.
13. [13] Schopman, J.E., Hoekstra, J.B.L., Holleman, F., et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab 17 (2015), 546–553.
14. [14] Hari Kumar, K.V., Shaikh, A., Prusty, P., Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 100 (2013), e55–e58.
15. [15] George, P.S., McCrimmon, R.J., Saxagliptin co-therapy in C-peptide-negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. Diabet Med 33:9 (2016 Sep), 1283–1290.
16. [16] Garg, S.K., Moser, E.G., Snell-Bergeon, J.K., et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 19 (2013), 19–28.
17. [17] Farngren, Johan, Persson, Margaretha, Schweizer, Anja, Foley, James E., Ahrén, Bo, Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol 97 (2012), 3799–3806.
18. [18] Frandsen, C.S., Dejgaard, T.F., Madsbad, S., Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 4:9 (2016 Sep), 766–780.
19. [19] Bode, B.W., Garg, S.K., The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr. Pract. 22 (2016), 220–230.
20. [20] Tölle, S., GLP-1 analogues in treatment of type 1 diabetes mellitus. Dtsch Med Wochenschr 139:42 (2014), 2123–2126.
21. [21] Pospisilik, J.A., Martin, J., Doty, T., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:3 (2003), 741–750.
22. [22] Pospisilik, J.A., Ehses, J.A., Doty, T., et al. Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol 524 (2003), 281–291.
23. [23] Kutoh, E., Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. J Med Case Rep, 5, 2011, 117.
24. [24] DeGeeter, M., Williamson, B., Alternative agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors. J Pharm Pract 29 (2016), 144–159.
25. [25] Kim, S.J., Nian, C., Doudet, D.J., et al. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58 (2009), 641–651.
26. [26] Kim, S.J., Nian, C., McIntosh, C.H., Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4 T-cell migration through incretin-dependent and -independent pathways. Diabetes 59 (2010), 1739–1750.
27. [27] Jelsing, J., Vrang, N., van Witteloostuijn, S.B., et al. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice. J Endocrinol 214 (2012), 381–387.
28. [28] Shimoda, S., et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocrine J 60 (2013), 1207–1214.
29. [29] Barbieri, M., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227 (2013), 349–354.